@conference{83d8aa58e0974f6aad2b102d12b39ced,
title = "Phase II trial of dovitinib in recurrent glioblastoma.",
author = "Ahluwalia, {Manmeet Singh} and Nikolaos Papadantonakis and Venur, {Vyshak Alva} and Cathy Schilero and Peereboom, {David M.} and Glen Stevens and Steven Rosenfeld and Vogelbaum, {Michael A.} and Paul Elson and Nixon, {Andrew B.} and Keith McCrae",
note = "2050 Background: Glioblastoma (GBM) is a vascular tumor and bevacizumab (a monoclonal antibody against VEGF-A) is FDA-approved in recurrence. Mechanisms of resistance to anti VEGF therapy include up-regulated FGF signaling and increased PDGF-mediated pericyte coverage. Dovitinibis an oral, small-molecule tyrosine kinase inhibitor of FGFR 1-3, PDGFR β, and VEGFR 1-3.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2015",
month = may,
day = "20",
doi = "10.1200/JCO.2015.33.15_SUPPL.2050",
language = "American English",
}